Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
113
-
Total 13F shares, excl. options
-
91.5M
-
Shares change
-
-6.3M
-
Total reported value, excl. options
-
$263M
-
Value change
-
-$28.7M
-
Put/Call ratio
-
1.68
-
Number of buys
-
52
-
Number of sells
-
-52
-
Price
-
$2.88
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2021
145 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q3 2021.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 91.5M shares
of 236M outstanding shares and own 38.71% of the company stock.
Largest 10 shareholders include STATE STREET CORP (15.9M shares), BlackRock Inc. (14.1M shares), VANGUARD GROUP INC (12.4M shares), MARSHALL WACE, LLP (6.97M shares), Nantahala Capital Management, LLC (4.98M shares), SATTER MANAGEMENT CO., L.P. (4.65M shares), GEODE CAPITAL MANAGEMENT, LLC (3.23M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2.66M shares), Woodline Partners LP (2.32M shares), and DIMENSIONAL FUND ADVISORS LP (2.1M shares).
This table shows the top 113 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.